Origene introduced this week its new high-density protein microarray chip for the quality control of its monoclonal antibodies.
The chip, which the company will feature at the American Association for Clinical Chemistry annual meeting next week in Atlanta, will enable Origene to screen its monoclonal antibodies against 10,000 human proteins to better ensure their specificity, the company said.